» Articles » PMID: 12902632

The Prognostic Significance in Goodpasture's Disease of Specificity, Titre and Affinity of Anti-glomerular-basement-membrane Antibodies

Overview
Publisher Karger
Specialty Nephrology
Date 2003 Aug 7
PMID 12902632
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The nephrotoxic potential of anti-glomerular-basement-membrane (GBM) antibodies has been demonstrated in numerous animal experiments. However, it is not known to what extent the properties of circulating anti-GBM antibodies in human disease reflect the severity of the disease and predict the outcome.

Methods: Clinical data were collected for 79 Swedish patients for whom a positive result had previously been obtained with anti-GBM ELISA. In stored sera from the patients, we measured antibody concentration, specificity and affinity together with antineutrophil cytoplasmic antibodies and alpha(1)-antitrypsin phenotype.

Results: Six months after diagnosis, 27 (34%) were dead, 32 (41%) were on dialysis treatment and only 20 (25%) were alive with a functioning native kidney. The best predictor for renal survival was renal function at diagnosis. In patients who were not dialysis dependent at diagnosis however, renal survival was associated with a lower concentration of anti-GBM antibodies, a lower proportion of antibodies specific for the immunodominant epitope and the histological severity of the renal lesion. The only factor that correlated with patient survival was age.

Conclusions: Immunochemical properties of autoantibodies do not affect patient survival in anti-GBM disease but seem to be a factor in renal survival in patients detected before renal damage is too advanced.

Citing Articles

Management dilemma of anti-GBM disease and p-ANCA-associated vasculitis with necrotizing skin lesions in a pediatric patient.

Chirico V, Silipigni L, Tripodi F, Conti G, Rulli I, Granata F Pediatr Nephrol. 2025; .

PMID: 40029412 DOI: 10.1007/s00467-025-06721-5.


Outcome of rituximab treatment in children with non-dialysis-dependent anti-GBM disease.

Klaus R, Kanzelmeyer N, Haffner D, Lange-Sperandio B Pediatr Nephrol. 2024; 40(2):423-430.

PMID: 39320552 DOI: 10.1007/s00467-024-06512-4.


Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment.

Tyrberg L, Andersson F, Uhlin F, Hellmark T, Segelmark M Nephrol Dial Transplant. 2023; 39(1):45-54.

PMID: 37385828 PMC: 10730795. DOI: 10.1093/ndt/gfad132.


Atypical Anti-Glomerular Basement Membrane Disease.

Bharati J, Yang Y, Sharma P, Jhaveri K Kidney Int Rep. 2023; 8(6):1151-1161.

PMID: 37284681 PMC: 10239794. DOI: 10.1016/j.ekir.2023.03.010.


Recurrent Nephritis and/or Pulmonary Hemorrhage in Patients with Anti-Glomerular Basement Membrane Disease with and without ANCA Positivity.

Droz N, Katz A, Patel A, Briskin I, Sedor J, Hajj Ali R Glomerular Dis. 2023; 1(2):60-67.

PMID: 36751425 PMC: 9677746. DOI: 10.1159/000515388.